The Rundown Eli Lilly's Weight-Loss Pill Trials Hit Big Milestone, Temu's App Downloads Plummet in Wake of Tariff War
Apr 17, 2025
Stock market turbulence takes center stage as comments from the Federal Reserve Chair lead to declines in major indexes. Eli Lilly celebrates significant progress in weight-loss treatment trials while Timu faces a sharp drop in app downloads amid tariff disputes. The tragic assassination of a UnitedHealth executive prompts a downward spiral in their stock, contrasting starkly with LVMH's falling stock value. Meanwhile, Hermes remains strong, showcasing resilience in the luxury market.
AI Snips
Chapters
Transcript
Episode notes
Powell Links Tariffs to Inflation
- Jerome Powell warned that Trump's tariffs could increase inflation and slow economic growth.
- This caused market sell-offs as investors feared persistent inflation due to trade tensions.
Eli Lilly Leads Weight Loss Market
- Eli Lilly's weight loss pill showed promising trial results with an average 16-pound loss over 40 weeks.
- The drug market here is huge, with projections hitting $130 billion by 2030, driving pharma competition.
Timu App Hit by Tariff Impact
- Timu's app downloads dropped 62% due to U.S. tariffs on Chinese goods and closing of the De Minimis loophole.
- These changes threaten Timu's low-price business model, forcing price increases and reduced advertising.